Sri Harsha Tella
Anuhya Kommalapati2
Mary Angelynne Esquivel
Ricardo Correa- 1Eunice Kennedy Shriver National Institutes of Child Health and Human Development, National Institutes of Health (NICHD/NIH), Bethesda, MD, United States
- 2Internal Medicine, Washington Hospital Center, Washington, DC, United States
- 3Endocrinology, Diabetes and Metabolism, Warren Alpert Medical School of Brown University, Providence, RI, United States
Well-differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy that has an excellent prognosis with a 5-year survival rate of about 98%. However, approximately 50% of the patients with DTC who present with distant metastases (advanced DTC) die from the disease within 5 years of initial diagnosis even after getting the appropriate therapy. Apart from recent advancements in chemotherapy agents, the potential role of metabolic interventions, including the use of metformin, ketogenic diet, and high-dose vitamin C in the management of advanced cancers have been investigated as a less toxic co-adjuvant therapies. The role of vitamin C has been of interest again after a preclinical mice study showed that high-dose vitamin C is selectively lethal to KRAS and BRAF mutant colorectal cancer cells by targeting the glutathione pathway. This raises the possibility of utilizing high-doses of vitamin C in the treatment of aDTC where KRAS and BRAF mutations are common. Similarly, alteration of cellular metabolism by low-carbohydrate ketogenic diets can be an important therapeutic strategy to selectively kill cancer cells that mainly survive on glycolysis. Among the potential adjuvant therapies proposed in this paper, metformin is the only agent that has shown benefit in human model of aDTC, the others have shown benefit but in preclinical/animal studies only and need to be further evaluated in large clinical trials. In conclusion, in addition to concurrent chemotherapy options, these metabolic interventions may have a great potential as co-adjuvant therapy in the management of aDTC.
Introduction
Well-differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy and is classified into three major categories: papillary thyroid carcinoma, follicular thyroid carcinoma, and Hürthle cell carcinoma. The incidence of DTC has grown in recent years due to availability of advanced and sensitive diagnostic tests, which has led to increased detection of micro-carcinomas. DTC has an excellent prognosis with a 5-year survival rate of about 98%. Despite low mortality, this disease has been treated aggressively for fear of more advanced disease and lack of effective tools for risk stratification. These aggressive treatments include high doses of radio-active iodine multiple times that have several side effects on other types of cells and chemotherapy that increase survival but decrease quality of life.
Given its typical protracted course and lack of effective treatments, aDTC can be considered a chronic disease, and safe and low-cost long-term interventions aiming at delaying or prevention of disease progression are more desirable. One such approach could be targeting reprogrammed glucose metabolism of advanced cancers, such as with metformin, ketogenic diet, and high-dose vitamin C (1, 2). These metabolic interventions open new doors with potential role as co-adjuvant therapy in the management of advanced differentiated thyroid malignancies.
Metformin
Diabetic patients treated with metformin were found to have a lower risk of cancer compared to those who were not on metformin (3, 4). Cancer-related mortality has also been shown to be lower in metformin users when compared to that of non-users (5). Moreover, observational studies in breast cancer have shown that metformin increased sensitivity of breast cancer cells to neoadjuvant therapy (6). A meta-analysis by Cazzaniga et al. (7) concluded that there was a 31% reduction in incidence and mortality from cancer in patients who were on metformin. In DTC patients, a single institutional observational study (8) showed that metformin-treated individuals had smaller tumor size, thus suggesting its potential for tumor growth inhibition. In addition, metformin treatment had also resulted in higher remission rates (8). Based on in vitro analysis of DTC cells, p70S6K/pS6 has been proposed as the most likely molecular target of metformin. By its insulin-sensitizing effect, metformin decreases insulin and insulin growth factor-1 (IGF-1) levels, which are mitogenic hormones. Metformin’s likely role as adjuvant therapy for advanced DTC should be explored further in larger prospective randomized placebo-controlled trials. If proven effective, metformin will be a great adjuvant anticancer agent for advanced DTC (and other cancers) because of its safety and widespread availability.
Ketogenic Diet
The Warburg effect (9) illustrates the metabolic shift in cancer cells where aerobic respiration is downregulated and glucose is preferentially used to generate energy. The preferential fermentation of glucose to lactate happens regardless of oxygen availability and complete mitochondrial function. Fluro deoxy glucose positron emission tomography scans (FDG-PET scans) utilize this mechanism in the diagnosis of cancer—cancer cells have a selectively enormous amount of glucose uptake compared to normal cells. The shift toward the glycolytic pathway is believed to be mediated by the activation of the insulin/IGF-1-dependent phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of the rapamycin (mTOR) system inappropriately, which promotes glucose uptake and trapping by GLUT receptors in cancer cells. Modulation of cellular metabolism by glucose depletion by using ketogenic diets has been proposed as a potential therapeutic strategy to selectively kill cancer cells. Although there is limited data from clinical studies, preclinical studies (10) have shown that the ketogenic diet is a viable option as an adjunct therapy for certain cancers, including advanced DTC.
Ketogenic diets consist of ingestion of very low-carbohydrate, moderate-protein, and high-fat foods, thereby causing preferential metabolism of fats compared to that of carbohydrates and proteins (11, 12). Because of elevated levels of fat-derived ketone bodies and corresponding decreased glucose levels in the blood, alterations in cellular metabolism occur. The ketogenic diet is also shown to reverse redox-signaling pathways that play an important role in tumorigenesis (13). Circulating glucose levels are depleted in the ketogenic diet, thereby compromising glucose metabolism and glucose-related signaling in tumor cells, which in turn results in concomitant reduction of blood insulin and IGF-1 levels, thus leading to downregulation of the PI3K/Akt/mTOR pathway and, in turn, impaired glycolytic metabolism (14). Moreover, in contrast to normal cells, malignant cells are unable to efficiently metabolize ketone bodies. The use of the ketogenic diet opens doors for the management of advanced thyroid cancer in combination with currently available therapies. On the other hand, one must be cautious that the low-carbohydrate diet can amplify cancer cachexia when continued for long periods of time.
High-Dose Vitamin C
Ascorbic acid (vitamin C) is an essential nutrient and a well-known antioxidant. In 1979, Nobel Prize winners Cameron and Pauling first studied the use of intravenous vitamin C (10 g per day) in 100 patients with various forms of advanced cancer. The results of the study were promising showing an improvement in survival by almost 20 times when compared with the control group (15). However, two other randomized controlled trials (16, 17) failed to replicate these results. It was not until recently that the role of vitamin C has been of interest again after a preclinical mice study (18) showed that high-dose vitamin C is selectively lethal to KRAS and BRAF mutant colorectal cancer cells by targeting the glutathione (GAPDH) pathway. This raises the possibility of utilizing vitamin C in the treatment of advanced thyroid cancers, where KRAS and BRAF mutations are common.
Preclinical studies (19) have shown that pharmacologic doses of vitamin C selectively act as a prooxidant in cancer cells thereby increasing the amount of reactive oxygen species (ROS) and exerting antitumorigenic activity. In fact, this prooxidant effect is seen only in tumor cells (19) but not in normal cells. It has been shown that KRAS and BRAF mutated cancer cells expressed more GLUT1 transporters that had led to increased uptake of vitamin C in its reduced form, dehydroascorbate (DHA). Inside cancer cells, DHA is converted back to vitamin C by glutathione (GSH). During this process, GSH is modified and becomes “oxidized glutathione,” which is further reduced to GSH by nicotinamide adenine dinucleotide phosphate (NADPH). High doses of vitamin C promote activation of ROS, and by this, GSH and NADPH are depleted. As previously alluded to, the presence of GLUT1 receptors on BRAF and KRAS mutated cells promotes this prooxidant effect of vitamin C in cancer cells. On the contrary, this effect was not seen in adenomatous polyposis coli mutated cells, which have less GLUT1 receptors on their cell surface. Interestingly, this lethal effect of high doses of vitamin C on cancer cells is masked in the presence of N-acetylcysteine, which is a potent antioxidant, thereby confirming the pro-oxidative nature of high doses of vitamin C. Hence, tumors that exhibit a high rate of ROS generation coupled with increased GLUT1 expression are likely to benefit from treatment with a high-dose of vitamin C (20). This effect can be taken advantage of and extended to DTC cells that are known to harbor the KRAS and BRAF mutations. It is important to note that future studies that aim to evaluate the beneficial effects of vitamin C in advanced DTC should use the drug intravenously to achieve adequate concentrations. Two randomized controlled trials (16, 17) failed to show the anticancer benefits of using vitamin C likely due to inadequate vitamin C concentrations as these trials had used the oral forms.
Conclusion
In summary, promising outcomes of vitamin C described in the management of KRAS and BRAF mutated colorectal cancer cells opened a new insight into treating aDTC. Similar positive results were seen with metformin and ketogenic diet as discussed above. Thus, we expect that metabolic interventions with high-dose vitamin C, ketogenic diet, and metformin can become an adjuvant therapy for patients with advanced differentiated thyroid cancer. It is interesting to note that all three metabolic interventions exert their effect via glycolytic pathways, which are predominantly activated in malignancies (the Warburg effect), particularly in advanced DTC.
These metabolic approaches combined with or without conventional standard therapies have great potential to be beneficial as co-adjuvant therapies in the treatment of advanced DTC. Throughput multicentric randomized trials involving multidisciplinary teams and the use of state-of-the-art technology are substantially needed for advancements in the therapies of aDTC.
Author Contributions
ST, AK, ME, and RC have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Benjamin D, Colombi M, Hindupur SK, Betz C, Lane HA, El-Shemerly MY, et al. Syrosingopine sensitizes cancer cells to killing by metformin. Sci Adv (2016) 2:e1601756. doi:10.1126/sciadv.1601756
2. Smyl C. Ketogenic diet and cancer – a perspective. Recent Results Cancer Res (2016) 207:233–40. doi:10.1007/978-3-319-42118-6_11
3. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 330(7503):1304–5. doi:10.1136/bmj.38415.708634.F7
4. Buchs AE, Silverman BG. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism (2011) 60(10):1379–85. doi:10.1016/j.metabol.2011.05.002
5. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab (2012) 14(1):23–9. doi:10.1111/j.1463-1326.2011.01480.x
6. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol (2009) 27(20):3271–3. doi:10.1200/JCO.2009.22.1630
7. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev (2009) 18(3):701–5. doi:10.1158/1055-9965.EPI-08-0871
8. Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab (2013) 98(8):3269–79. doi:10.1210/jc.2012-3799
9. Warburg O. The metabolism of carcinoma cells. J Cancer Res (1925) 9:148–63. doi:10.1158/jcr.1925.148
10. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One (2014) 9(12):e115147. doi:10.1371/journal.pone.0115147
11. Lima PA, Sampaio LP, Damasceno NR. Neurobiochemical mechanisms of a ketogenic diet in refractory epilepsy. Clinics (Sao Paulo) (2014) 69(10):699–705. doi:10.6061/clinics/2014(10)09
12. Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA, et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol (2014) 2:963–70. doi:10.1016/j.redox.2014.08.002
13. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) (2010) 7:74. doi:10.1186/1743-7075-7-74
14. Branco AF, Ferreira A, Simoes RF, Magalhaes-Novais S, Zehowski C, Cope E, et al. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest (2016) 46(3):285–98. doi:10.1111/eci.12591
15. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A (1976) 73(10):3685–9. doi:10.1073/pnas.73.10.3685
16. Moertel CG, Fleming TR, Creagan ET, Rubin J, O’Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 312(3):137–41. doi:10.1056/NEJM198501173120301
17. Creagan ET, Moertel CG, O’Fallon JR, Schutt AJ, O’Connell MJ, Rubin J, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 301(13):687–90. doi:10.1056/NEJM197909273011303
18. Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K, et al. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science (2015) 350(6266):1391–6. doi:10.1126/science.aaa5004
19. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 105(32):11105–9. doi:10.1073/pnas.0804226105
Keywords: vitamin C, ketogenic diet, metformin, differentiated thyroid cancer, BRAF, KRAS, GLUT1, glutathione
Citation: Tella SH, Kommalapati A, Esquivel MA and Correa R (2017) Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. Front. Oncol. 7:160. doi: 10.3389/fonc.2017.00160
Received: 29 May 2017; Accepted: 12 July 2017;
Published: 25 July 2017
Edited by:
Angela Hague, University of Bristol, United KingdomReviewed by:
Veronica Vella, Kore University of Enna, ItalyMarco Falasca, Curtin University, Australia
Copyright: © 2017 Tella, Kommalapati, Esquivel and Correa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ricardo Correa, riccorrea20@hotmail.com, ricardo.correa@brown.edu